Motif Neurotech announced on April 27 that the FDA has approved the company’s investigational device exemption to begin a first-in-patient clinical trial of DOT, a millimeter-scale wireless brain stimulator implanted between the skull and the dura, targeting treatment-resistant depression. The clearance is the most significant regulatory milestone for the Rice University spinout since its first-in-human demonstration in 2024, which used the same device to evoke motor responses by stimulating the motor cortex. STAT, MassDevice, and BusinessWire all carried the IDE approval news.
DOT lands in a category that has consumed and defeated every previous serious attempt: implantable therapies for depression. Medtronic’s Reclaim DBS programme failed its pivotal trial in 2013. Abbott’s BROADEN trial for depression DBS was halted for futility. The procedural cost, surgical invasiveness, and patient-acceptance burden of full deep-brain stimulation have kept implantable depression devices outside the realistic commercial frame for most of the last two decades. Motif’s bet is that miniaturisation and minimally-invasive placement collapse those barriers far enough to redraw the field.
The DOT design
DOT is roughly 9 millimetres wide. It is implanted in an outpatient procedure that reaches the bone over the brain without exposing or contacting cortical tissue. Motif says the surgery can be performed in around twenty minutes by surgeons with minimal training. The implant is battery-free. Power and data are delivered wirelessly via magnetoelectric transfer: an external transmitter, designed to be worn on the head as a cap or similar wearable, generates an oscillating magnetic field that the implant converts into electrical pulses delivered to the brain through the dura. Peak stimulation output reaches roughly 14.5 volts.
For depression, the target is the dorsolateral prefrontal cortex, the same region targeted by transcranial magnetic stimulation, the leading non-invasive depression therapy currently in widespread clinical use. The conceptual framing is straightforward: take what TMS does in 30-minute clinic sessions and turn it into a daily-use, patient-controlled, always-available stimulus delivered at home or at work whenever the wearable is donned.
The Rice and Hodak provenance
Motif emerged from the Rice University laboratory of Jacob Robinson, who serves as the company’s chief executive. The wireless power technology underlying DOT was patented at Rice and is exclusively licensed to Motif. Early prototypes were funded by the Defense Advanced Research Projects Agency. The company subsequently closed an oversubscribed $18.75 million Series A, with total venture financing now exceeding $20 million across Arboretum Ventures, re.Mind Capital, Dolby Family Ventures, and KdT Ventures.
Among the named individual backers is Max Hodak, the former president and chief executive of Neuralink and a member of Neuralink’s founding team. Hodak’s involvement matters as a signal more than as a sum. Every credible founder evaluating implantable mental-health BCI as a category looks closely at where the early Neuralink alumni place their bets. The Motif investment cohort also includes one of Neuralink’s first investors who sat on Neuralink’s founding team.
The depression-implantable problem
The strategic question DOT is built to answer is whether an implant can be small enough, fast enough to place, and casual enough in patient experience that the calculus of implant versus another antidepressant trial tips toward the implant. Treatment-resistant depression affects roughly a third of the estimated 280 million people globally living with major depressive disorder. The current ladder runs: SSRIs, SNRIs, augmentation strategies, ketamine-class therapies, transcranial magnetic stimulation, electroconvulsive therapy, and, for a tiny minority, DBS. DBS sits at the bottom of the ladder for reasons of cost, invasiveness, and uneven trial outcomes.
DOT is a deliberate attempt to insert a new rung between TMS and DBS. The pitch is that an epidural, minimally invasive, daily-use device delivers a TMS-grade stimulation profile without the clinic-bound delivery model and without the deep-brain surgical burden. If the feasibility trial supports that thesis with durable symptom reduction in treatment-resistant patients and manageable safety, Motif moves from a Rice spinout with a science demo into a commercially viable mental-health BCI category.
Trial design details, including sample size, number of sites, primary endpoint, and follow-up duration, will be published as the protocol is formally registered. Motif’s patient registry, opened in late 2025 to identify potential study candidates, gives the company a head-start on enrolment relative to standard first-in-patient depression studies.
The wider lens
Motif’s IDE clearance arrives in the same week that CorTec joined the FDA’s Total Product Life Cycle Advisory Programme and that Orchestra BioMed presented MODERATO II hypertension data through the Medtronic-partnered AVIM platform. The pattern across all three is consistent. The implantable-bioelectronic field is moving past the question of whether non-arrhythmia indications can support implant economics, and into the question of which architectural approach wins. Motif’s answer is wireless, miniaturised, epidural, and patient-controlled. The trial will tell whether that answer survives contact with depression, the indication that has buried more implantable therapies than any other.